Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 6

1.

Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways.

Santinon G, Pocaterra A, Dupont S.

Trends Cell Biol. 2016 Apr;26(4):289-99. doi: 10.1016/j.tcb.2015.11.004. Epub 2015 Dec 30. Review.

PMID:
26750334
2.

Differential control of Yorkie activity by LKB1/AMPK and the Hippo/Warts cascade in the central nervous system.

Gailite I, Aerne BL, Tapon N.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):E5169-78. doi: 10.1073/pnas.1505512112. Epub 2015 Aug 31.

3.

Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids.

Peart T, Ramos Valdes Y, Correa RJ, Fazio E, Bertrand M, McGee J, Préfontaine M, Sugimoto A, DiMattia GE, Shepherd TG.

Oncotarget. 2015 Sep 8;6(26):22424-38.

4.

LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.

Han D, Li SJ, Zhu YT, Liu L, Li MX.

Asian Pac J Cancer Prev. 2013;14(7):4033-9. Review.

5.

Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease.

Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A, Wands JR.

J Hepatol. 2013 Apr;58(4):785-91. doi: 10.1016/j.jhep.2012.11.042. Epub 2012 Dec 2.

6.

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.

Shackelford DB, Shaw RJ.

Nat Rev Cancer. 2009 Aug;9(8):563-75. doi: 10.1038/nrc2676.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk